What is Sera Prognostics?
Sera Prognostics is a specialized biotechnology firm dedicated to transforming maternal health through advanced diagnostic solutions. The company develops sophisticated tests that provide physicians and patients with actionable insights into individualized risks for pregnancy complications, including preeclampsia and preterm birth. By leveraging biological data to predict these outcomes, the company empowers clinical teams to implement proactive care strategies, ultimately aiming to improve neonatal and maternal health outcomes. Its market position is defined by a commitment to precision medicine and the integration of its diagnostic tools into standard prenatal care workflows.
How much funding has Sera Prognostics raised?
Sera Prognostics has raised a total of $325M across 11 funding rounds:
Debt
$4.5M
Private Equity
$9.2M
Private Equity
$5M
Series B
$25M
Debt
$10M
Series C
$40M
Series D
$36M
Debt
$1M
Series E
$100M
Share Placement
$75M
Debt (2013): $4.5M led by Linden, UpStart Ventures, Catalyst Health Ventures, and InterWest Partners
Private Equity (2014): $9.2M, investors not publicly disclosed
Private Equity (2014): $5M, investors not publicly disclosed
Series B (2015): $25M backed by Bill & Melinda Gates Foundation, InterWest Partners, Catalyst Health Ventures, and Domain Associates
Debt (2015): $10M with participation from Square 1 Bank
Series C (2017): $40M led by Domain Associates, Laboratory Corporation of America, Bill & Melinda Gates Foundation, InterWest Partners, and Catalyst Health Ventures
Series D (2019): $36M supported by Catalyst Health Ventures, InterWest Partners, Domain Associates, Blue Ox Healthcare Partners, Chione , Ltd, and Labcorp
Debt (2020): $1M featuring PPP
Series E (2021): $100M backed by Vivo Capital, Parian Global, aMoon, Blue Ox Healthcare Partners, and Anthem
Share Placement (2021): $75M, investors not publicly disclosed
Key Investors in Sera Prognostics
Domain Associates
DomainVC is an investment advisory firm established in 1985, specializing in biotech investments. The firm has provided VC funding to 194 biopharmaceutical, device, and diagnostic companies, resulting in 90 IPOs and 110 M&A events.
Catalyst Health Ventures
Catalyst Health Ventures is dedicated to enhancing the health innovation ecosystem by leveraging a global network and validated methodologies to facilitate strategic partnerships between innovators and healthcare companies.
Labcorp
Labcorp Holdings Inc. is a global laboratory services company that provides vital diagnostic information to help doctors, hospitals, and patients make clear and confident healthcare decisions.
What's next for Sera Prognostics?
With the recent influx of capital, Sera Prognostics is poised to enter a critical phase of market expansion and clinical adoption. The strategic focus will likely shift toward broadening the accessibility of its diagnostic suite and deepening partnerships with major healthcare providers and managed care organizations. As the company matures, the emphasis will remain on validating the long-term economic and clinical value of its tests, ensuring that its technology becomes a cornerstone of modern obstetric care. Continued investment will support the scaling of its laboratory infrastructure and the pursuit of further regulatory milestones to solidify its leadership in the precision maternal health sector.
See full Sera Prognostics company page
